Efficacy of Nucleoside Analogs for Chronic Hepatitis B Virus-Related Hepatocellular Carcinoma After Curative Treatment: A Meta-Analysis
Background and Aim
The efficacy of nucleoside analogs (NAs) for hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) after curative treatment remains unclear. The present study aimed to evaluate the efficacy of these agents by conducting a comprehensive meta-analysis of available studies.
We searched several databases including Pubmed, Embase, Cochrane Library, Clinical Trials, and Web of Science, according to PRISMA guidelines. We considered all randomized controlled trials and cohort studies that met the inclusion criteria. Statistical analyses were conducted using Review Manager 5.3 and Stata 14.0.
Twenty-one studies with 8752 participants were included in the final analysis. The pooled data showed that patients treated with NAs had significantly lower 1- and 3-year HCC recurrence rates (relative risk [RR] 0.76, 95% confidence interval [CI] 0.65–0.90; P = 0.001 and RR 0.79, 95% CI 0.71–0.88; P < 0.001, respectively), but there was no difference in 5-year recurrence rates (RR 0.87, 95% CI 0.74–1.03; P = 0.10). Regarding overall survival (OS), patients treated with NAs had significantly higher 1-, 3-, and 5-year OS rates (RR 1.05, 95% CI 1.02–1.08; P = 0.003; RR 1.25, 95% CI 1.16–1.34; P < 0.001; and RR 1.28, 95% CI 1.18–1.39; P < 0.001, respectively).
NA therapy has the potential to reduce the risk of early recurrence and improve OS in patients with HBV-related HCC after curative treatment, compared with placebo or no treatment. Further research including more homogeneous studies with large sample sizes is required to improve the reliability of these conclusions.
KeywordsNucleoside analog Hepatocellular carcinoma Curative treatment Meta-analysis
This study was funded by the National Natural Science Foundation of China (No. 81760497).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 10.Weis S, Franke A, Mossner J, Jakobsen JC, Schoppmeyer K. Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma. Cochrane Database Syst Rev. 2013;12:Cd003046.Google Scholar
- 23.Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed July 6, 2014.
- 26.Wei Q, Xu X, Ling Q, Zheng S. Indefinite antiviral therapy may be required after surgical resection for hepatocellular carcinoma complicating chronic hepatitis. Bos J Res Med Sci. 2013;18:726–730.Google Scholar
- 47.Yan Q, Ni J, Zhang GL, et al. Efficacy of postoperative antiviral combined transcatheter arterial chemoembolization therapy in prevention of hepatitis B-related hepatocellular carcinoma recurrence. Chin Med J (Engl). 2013;126:855–859.Google Scholar
- 59.Xia BW, Zhang YC, Wang J, Ding FH, He XD. Efficacy of antiviral therapy with nucleotide/nucleoside analogs after curative treatment for patients with hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2015;39:458–468.CrossRefGoogle Scholar